RxDoctor Payments Data

Charles Kerr, MD

Family Medicine · Andalusia, ALNPI 1790798973

Payments from drug & device makers

$317in general payments, 2019–2025

Across 21 payments — averaging $15.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$93
  • Lilly USA, LLC$58
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$43
  • Kowa Pharmaceuticals America, Inc.$31
  • Johnson & Johnson$28
  • Novo Nordisk$25
  • plus $38 from 2 others

What the payments were for

  • Food & beverage$30596%
  • Education$124%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$317 in reported general payments places this provider in the 35th percentile of 1,680 family medicine providers in Alabama.

See all family medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$187,055
Medicare patients
239
Services billed
8,639

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide134$157,384
EliquisApixaban127$137,705
XareltoRivaroxaban49$57,985
Repatha SureclickEvolocumab68$56,923
MounjaroTirzepatide38$47,601
JanuviaSitagliptin Phosphate41$44,875
TrulicityDulaglutide37$35,054
MyrbetriqMirabegron46$33,816
MultaqDronedarone Hcl25$26,877
Rosuvastatin Calcium552$16,728
Trelegy ElliptaFluticasone/Umeclidin/Vilanter25$16,042
Potassium Chloride255$10,884
Breo ElliptaFluticasone/Vilanterol26$10,856
Ezetimibe235$9,781
Spiriva RespimatTiotropium Bromide14$8,518

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$25$157,384134 claims
PfizerEliquis$93$137,705127 claims
Lilly USA, LLCMounjaro, Trulicity$58$82,65575 claims
Johnson & JohnsonXarelto$28$57,98549 claims
AbbVieSynthroid$25$4,45036 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 1,680 family medicine providers in Alabama.

Other family medicine in Andalusia

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →